The present invention relates to a nanoparticle for use in the treatment of ocular diseases, in particular diseases of the retina (“retinopathies”) or of optic neuropathies, in particular glaucoma.

The present invention relates to a nanoparticle for use in the treatment of ocular diseases, in particular diseases of the retina (“retinopathies”) or of optic neuropathies, in particular glaucoma.

Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.

The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.

A pharmaceutical composition containing an Akkermansia muciniphila EB-AMDK19 strain or a culture or dried product thereof and uses thereof are disclosed. The composition is effective for the prevention or treatment of atopic disease. The pharmaceutical composition exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

A pharmaceutical composition containing an Akkermansia muciniphila EB-AMDK19 strain or a culture or dried product thereof and uses thereof are disclosed. The composition is effective for the prevention or treatment of atopic disease. The pharmaceutical composition exhibits a preventive or therapeutic effect on atopic disease at the same level as that of steroid-based drugs, and thus is not only promising as pharmabiotics, but also useful in the development of food and cosmetics.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.